Infectious Disease Advisor: Real-world data on BIC/FTC/TAF switch and long-acting ART in patients with viremia
Recent studies indicate that switching to the BIC/FTC/TAF regimen is effective for virologically suppressed HIV patients. Additionally, real-world data supports the use of long-acting antiretroviral therapy for individuals with HIV.
Why it matters
Advancements in HIV treatment regimens improve patient outcomes and simplify long-term management of the virus.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Switching to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) represents a safe and effective regimen-optimization strategy among individuals with HIV who are virologically suppressed on antiretroviral therapy, according to study findings published in Infectious Diseases and Therapy .
Real-world data support long-acting antiretroviral therapy (ART) for people with HIV, including among those who are viremic at initiation, according to study findings published in Clinical Infectious Diseases .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in